JinSystem "Leap to 'Rapid On-site Molecular Diagnostic Platform Global Leader' through Listing"

[Asia Economy Reporter Yoo Hyun-seok] "We aim to achieve sales of 150 billion KRW by 2025 through diversifying our diagnostic kit portfolio and fully launching our platform business. Through this, we will leap forward as a global leader in rapid on-site molecular diagnostic platforms."

Seo Yoo-jin, CEO of Jin System, announced this goal at an IPO briefing held on the 6th in Yeouido.

Jin System was established in 2010 and operates its business centered on rapid on-site molecular diagnostic platforms. The company's platform refers to a solution encompassing diagnostic equipment and biochip-based diagnostic kits. By combining the advantages of molecular diagnostics and immunodiagnostics, they developed a diagnostic platform that is rapid, accurate, and easy to test. Last year, the company recorded sales of 13.3 billion KRW and an operating profit of 3.3 billion KRW. Sales surged by 1068.10%, and operating profit turned positive.

Jin System holds three core original technologies related to molecular diagnostic platforms: ▲Precision hardware technology ▲High Multiplex technology ▲Biochip technology. Their rapid PCR technology, which won the Presidential Award at the 2013 Korea Invention Patent Exhibition, achieves ultra-fast temperature control by adopting a thin plate-type heat block that improves heat transfer efficiency, unlike conventional PCR technology. This shortened the long PCR reaction time and secured price competitiveness. Through commercialization of core technologies, the company has expanded globally since 2016 to Japan, the United States, India, China, Europe, and the Middle East.

CEO Seo Yoo-jin said, "With population aging and rising income levels, interest in healthcare and early diagnosis is increasing, and the molecular diagnostics market, which can provide rapid and accurate diagnostic results, is expected to expand. Jin System is leading the paradigm shift in the changing global molecular diagnostics market by building a differentiated platform."

After listing, Jin System plans to advance its lineup of platform equipment and expand installation areas. They plan to commercialize the UF-400, capable of ultra-fast one-step real-time diagnostic target detection, by 2022. Additionally, as part of business diversification, they will commercialize new content targeting diseases with high diagnostic market potential and expand their product portfolio from human diagnostics to food inspection and the companion animal market to secure growth and profitability.

CEO Seo Yoo-jin emphasized, "Through this KOSDAQ listing, while we have focused on creating a happy company for customers and employees, we will now do our best to bring great happiness to shareholders who trust and invest in Jin System. We will grow into the world's top on-site molecular diagnostics company within 10 years by expanding diagnostic equipment installation areas and diversifying diagnostic kits."

Jin System is offering a total of 1,425,000 shares. The expected offering price is between 16,000 and 20,000 KRW, with a total offering amount of approximately 22.8 to 28.5 billion KRW. The raised funds will be invested in production facility investment, research and development (R&D), clinical trials, and certification costs. Demand forecasting will be conducted over two days from today until the 7th, followed by subscription on the 13th and 14th, with plans to list on the KOSDAQ market within the first half of the year. Samsung Securities is the lead underwriter.

This content was produced with the assistance of AI translation services.